Biomea Fusion, Inc. Share Price

Equities

BMEA

US09077A1060

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 13/06/2024 am IST 5-day change 1st Jan Change
4.63 USD +4.51% Intraday chart for Biomea Fusion, Inc. -60.90% -68.11%
Sales 2024 * - Sales 2025 * 21.43L 18Cr Capitalization 17Cr 1.39TCr
Net income 2024 * -15Cr -1.29TCr Net income 2025 * -16Cr -1.37TCr EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 77.7 x
P/E ratio 2024 *
-1.13 x
P/E ratio 2025 *
-1.35 x
Employees 110
Yield 2024 *
-
Yield 2025 *
-
Free-Float 74.86%
More Fundamentals * Assessed data
Dynamic Chart
1 day+4.51%
1 week-60.90%
Current month-55.99%
1 month-56.53%
3 months-70.36%
6 months-65.88%
Current year-68.11%
More quotes
1 week
3.61
Extreme 3.61
4.85
1 month
3.61
Extreme 3.61
13.43
Current year
3.61
Extreme 3.61
20.21
1 year
3.61
Extreme 3.61
40.83
3 years
2.84
Extreme 2.84
43.69
5 years
2.84
Extreme 2.84
43.69
10 years
2.84
Extreme 2.84
43.69
More quotes
Managers TitleAgeSince
Chief Executive Officer 43 01/17/01
Founder 60 01/17/01
Director of Finance/CFO 43 26/21/26
Members of the board TitleAgeSince
Founder 60 01/17/01
Director/Board Member 50 16/21/16
Director/Board Member 55 01/20/01
More insiders
Date Price Change Volume
12/24/12 4.63 +4.51% 2,269,537
11/24/11 4.43 +2.78% 2,642,768
10/24/10 4.31 +4.11% 5,331,940
07/24/07 4.14 -63.27% 11,882,758
06/24/06 11.27 -4.81% 1,196,224

Delayed Quote Nasdaq, June 13, 2024 at 01:30 am IST

More quotes
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
4.63 USD
Average target price
24.43 USD
Spread / Average Target
+427.61%
Consensus